行情

IGC

IGC

India全球化资本
AMEX

实时行情|Nasdaq Last Sale

1.510
-0.010
-0.66%
交易中 10:42 09/23 EDT
开盘
1.530
昨收
1.520
最高
1.535
最低
1.510
成交量
12.99万
成交额
--
52周最高
4.650
52周最低
1.010
市值
7,517.39万
市盈率(TTM)
-7.5841
分时
5日
1月
3月
1年
5年
美股开盘 | 三大指数齐跌 水滴(WDH.US)盘初涨近12%
美股开盘 | 三大指数齐跌 水滴(WDH.US)盘初涨近12%
智通财经 · 09/08 13:30
IGC、NCMI 和 BBIG 是上市前的赢家
Kadmon Holdings (NASDAQ:KDMN) +74% Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B Gain Therapeutics (NASDAQ:GANX) +27% on positive GT-02287and GT-02329 data in Parkinson’s disease Alset EHome International (NASDAQ:AEI) +15% inv...
Seekingalpha · 09/08 12:21
21 只股票在周三的盘前交易时段内波动
Gainers Kadmon Holdings, Inc. (NASDAQ: KDMN) rose 75.7% to $9.31 in pre-market trading after France's Sanofi announced plans to buy the company in a $1.9 billion deal.
Benzinga · 09/08 11:29
India Globalization Capital 称其 IGC-AD1 在阿尔茨海默病 1 期试验中是安全的
MT Newswires · 09/08 11:01
India Globalization(IGC.US)盘前涨超16% 新药IGC-AD1完成1期临床试验
India Globalization(IGC.US)盘前涨超16% 新药IGC-AD1完成1期临床试验
格隆汇 · 09/08 08:36
美股异动 | India Globalization Capital(IGC.US)盘前涨近24%,旗下新药完成1期临床试验
美股异动 | India Globalization Capital(IGC.US)盘前涨近24%,旗下新药完成1期临床试验
智通财经 · 09/08 08:10
盘后股价涨超22%!India Globalization Capital(IGC.US)宣布旗下新药完成1期临床试验
盘后股价涨超22%!India Globalization Capital(IGC.US)宣布旗下新药完成1期临床试验
智通财经 · 09/08 06:19
IGC 完成阿尔茨海默病患者的 1 期临床试验,报告安全性和耐受性
POTOMAC, Md., September 07, 2021--IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability.
Business Wire · 09/07 23:30
更多
财务预测
暂无数据
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解IGC最新的财务预测,通过IGC每股收益,每股净资产,每股现金流等数据分析India全球化资本近期的经营情况,然后做出明智的投资选择。
暂无数据
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
商业支持服务
+1.67%
专业与商业服务
+1.17%
高管信息
Non-Executive Chairman/Independent Director
Richard Prins
President/Chief Executive Officer/Director
Ram Mukunda
Chief Financial Officer/Vice President
Claudia Grimaldi
Chief Accounting Officer
Rohit Goel
Independent Director
John Lynch
暂无数据
IGC 简况
India Globalization Capital, Inc. (IGC) is engaged in the development of cannabinoid-based therapies for indications such as Alzheimer's disease and pain. IGC operates through two segments: Life Sciences and Infrastructure. Life Sciences segment involves the development of potential new drugs, hand sanitizers and several hemp-based Cannabidiol (CBD) products and brands, wholesale of hemp extracts, including hemp crude extract and hemp isolate, among others, white labeling of hemp-based products, and offering of tolling services like extraction and distillation to hemp farmers. Infrastructure segment involves execution of construction contracts, rental of heavy construction equipment and purchase and resale of physical commodities used in infrastructure. IGC'S Life Sciences brands include Hyalolex, Holi Hemp, Holief, Herbo, and Sunday Seltzer.

微牛提供India Globalization Capital, Inc.(AMEX-IGC)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IGC股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IGC股票基本功能。